Evidence map›Paper›PMID 31919358›Full record

ArticleNature communications2020

GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis.

Daniel Regan-Komito, James W Swann, Philippos Demetriou, E Suzanne Cohen, Nicole J Horwood, Stephen N Sansom, Thibault Griseri

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 107 citations in OpenAlex.

  1. CD200Nature communications · 2026
    Article
  2. iScience · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. HSPCs and TScience advances · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Daniel Regan-KomitoKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Roosevelt Drive, Oxford, UK.ORCID http://orcid.org/0000-0003-4840-9406
James W SwannKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Roosevelt Drive, Oxford, UK.ORCID http://orcid.org/0000-0001-7988-9997
Philippos DemetriouKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Roosevelt Drive, Oxford, UK.
E Suzanne CohenBiopharmaceutical Research Division, AstraZeneca, Cambridge, UK.
Nicole J HorwoodKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Roosevelt Drive, Oxford, UK.ORCID http://orcid.org/0000-0002-6344-1677
Stephen N SansomKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Roosevelt Drive, Oxford, UK.ORCID http://orcid.org/0000-0003-4569-8513
Thibault GriseriKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Roosevelt Drive, Oxford, UK. thibault.griseri@kennedy.ox.ac.uk.ORCID http://orcid.org/0000-0001-5739-7625
University of Oxford · GBAstraZeneca (United Kingdom) · GBNuffield Orthopaedic Centre · GBUniversity of East Anglia · GB

Funding

Medical Research Council G0900160Wellcome Trust
6 · The paper itself

Abstract

Dysregulated hematopoiesis occurs in several chronic inflammatory diseases, but it remains unclear how hematopoietic stem cells (HSCs) in the bone marrow (BM) sense peripheral inflammation and contribute to tissue damage in arthritis. Here, we show the HSC gene expression program is biased toward myelopoiesis and differentiation skewed toward granulocyte-monocyte progenitors (GMP) during joint and intestinal inflammation in experimental spondyloarthritis (SpA). GM-CSF-receptor is increased on HSCs and multipotent progenitors, favoring a striking increase in myelopoiesis at the earliest hematopoietic stages. GMP accumulate in the BM in SpA and, unexpectedly, at extramedullary sites: in the inflamed joints and spleen. Furthermore, we show that GM-CSF promotes extramedullary myelopoiesis, tissue-toxic neutrophil accumulation in target organs, and GM-CSF prophylactic or therapeutic blockade substantially decreases SpA severity. Surprisingly, besides CD4

Indexed as

AnimalsCD4-Positive T-LymphocytesCell DifferentiationCells, CulturedFemaleGranulocyte-Macrophage Colony-Stimulating FactorHematopoiesis, ExtramedullaryHematopoietic Stem CellsInterleukin-33Mast CellsMiceMice, Inbred BALB CMyelopoiesisSpondylarthritisGranulocyte-Macrophage Colony-Stimulating FactorIl33 protein, mouseInterleukin-33

Identifiers

PMID31919358
PMCPMC6952438
OpenAlexW2999595676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.